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BRIEF COMMUNICATION
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ABSTRACT
Molecular risk stratification of colorectal cancer can improve patient outcome. A panel of lncRNAs (H19,
HOTTIP, HULC and MALAT1) derived from serum exosomes of patients with non-metastatic CRC and
healthy donors was analyzed. Exosomes from healthy donors carried significantly more H19, HULC and
HOTTIP transcripts in comparison to CRC patients. Correlation analysis between lncRNAs and clinical data
revealed a statistical significance between low levels of exosomal HOTTIP and poor overall survival. This
was confirmed by multivariate analysis that HOTTIP is an independent prognostic marker for overall
survival (HR: 4.5, CI: 1.69–11.98, p = 0.0027). Here, HOTTIP poses to be a valid biomarker for patients with
a CRC to predict post-surgical survival time.
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Colorectal cancer (CRC) is one of themost frequent cancers world-
wide [1], despite decreasing incidence and mortality. Detection at
early stage is the most effective marker for best overall survival.
However, most patients present with advanced disease at time of
diagnosis and patientswith stage 4 disease have a poor 5 year overall
survival [2,3]. The current molecular risk classification of CRC is
based on histopathologymarkers such as stage, grade of differentia-
tion and lymphnode invasion, which are crucial to assess the tumor
initially, but fail to recapitulate the heterogeneity in CRC and its
associated wide range of treatment response and overall outcome.
There is an urgent clinical need to identify pivotal biomarkers and
combine these with the genetic information of a patient’s tumor to
improve an accurate prognosis and predict treatment response, risk
of progression and overall survival.
Liquid biopsies can be used as a minimal invasive tool to
determine malignancies, monitor disease progression and treat-
ment response [4]. Exosomes, commonly found in body fluids, are
extracellular vesicles that can contain cell-derived proteins, lipids
and nucleic acids includingmicroRNAand long non-coding RNA
(lncRNA), and have attracted remarkable interest to detect and
monitor diseases [5]. LncRNAs are a subclass of non-protein
coding RNAs involved in the gene regulation of cell growth,
invasion, and other critical cellular functions [6,7]. They are
often expressed in a disease- and tissue-specific manner making
thesemolecules attractive therapeutic targets, and pointing toward
specific functions for lncRNAs in development and diseases [8–
10]. Recent studies have shown that serum-derived exosomes from
cancer patients have a different lncRNA profile in comparison
with healthy donors or patients with a non-malignant disease
[11–13].
This study aimed to evaluate whether exosomal lncRNAs
can be used as minimal-invasive diagnostic and prognostic
markers in CRC. Specifically, we investigated the abundance
of four lncRNAs that have been associated with the epithelial-
to-mesenchymal transition [8,9] and metastasis [8] in serum-
derived exosomes from patients with non-metastatic CRC and
healthy controls in two independent cohorts.
Materials and methods
Patient characteristics and data collection
Serum collection was approved by the Ethics Committee of
the University of Heidelberg and the Ethics Committee of the
University of Dresden. Cohort 1 consists of 52 patients with
CRC that underwent tumor resection between 2007 and 2009
at the Department of Surgery, University of Heidelberg.
Serum samples from 52 healthy donors were included as
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a control. Cohort 2 consists of 48 patients with primary CRC
that underwent tumor resection between 2015 and 2016 at the
Department of Surgery, University of Dresden. As controls,
serum samples from 24 healthy donors were included. Clinical
information was obtained for all patients such as age, gender,
TNM classification, grading and treatment with chemother-
apy. Overall survival data was available for cohort 1, however
outcome data of cohort 2 is currently not available.
Blood collection and isolation of serum exosomes
Blood collection was performed as described recently [11].
Briefly, after blood collection, tubes were immediately centri-
fuged at 2500g for 10min, and separated serum was stored at
−80°C. For exosome isolation, serum samples were thawed on
ice. Subsequently, exosomes were isolated using an exosome
isolation kit (ThermoFisher Scientific®, Cat-Nr.: 4478360) fol-
lowing the manufacturer’s instructions. Exosome validation
included nanoparticle tracking analysis (ZetaView®, Particle
Metrix GmbH) and immunoblotting of exosomal markers.
Nanoparticle tracking analysis including fluorescent
mode by Zetaview®
Nanoparticle tracking analysis (NTA) was conducted using
ZetaView® to determine the concentration and size of the
extracted exosomes according to the manufacturer’s instruc-
tions. In addition, the fluorescent mode of ZetaView® was
employed to measure exosomal markers on the surface of
the extracted extracellular vesicles. For this analysis, 6.6*10
[9] exosomes were resuspended in 100µl 1xPBS and incubated
with 0.3µm polystyrene latex beads (Sigma-Aldrich, Cat.Nr.:
LB30–1ML) on a horizontal shaker with 1000rpm for 15min.
Subsequently, this suspension was diluted to 1ml with PBS
and incubated on a horizontal shaker with 600rpm for 60min.
For blocking, 100mM glycine and 1% BSA in PBS was added
and incubated for 30min. The suspension was centrifuged at
14.000g for 3min, and the bead-bound exosomes were recov-
ered as a pellet. The pellet was diluted in 40µl PBS and divided
into two equal volumes. One aliquot was incubated with
primary antibodies (CD81 polyclonal rabbit, dilution 1:20,
Novus Biologicals, Cat.Nr.: NBP2–20564; CD63 polyclonal
rabbit, dilution 1:20, Santa Cruz, Cat.Nr. sc-15363; CD9
monoclonal rabbit, dilution 1:20, Abcam, Cat.Nr.: ab92726;
TSG101, monoclonal mouse, dilution: 1:100, Abcam, Cat.Nr.:
ab83), the second aliquot was used as negative control. After
1hr of incubation, the reaction was stopped by adding block-
ing solution. Subsequently, the suspension was centrifuged at
14.000g for 3min, and the bead-bound exosomes were recov-
ered as a pellet. The Alexa-488 secondary antibody (Life
Technologies, NY 14,072, USA, anti-rabbit: A11034 or anti-
mouse: A11029) was added to all aliquots and incubated for
60min. After washing with 1x PBS/2% BSA, the pellet was
diluted in 1ml 1x PBS. The fluorescent bead-bound exosomes
(positive staining and negative control) were analyzed using
ZetaView® and ZetaView® 8.03.04.01 Software.
Transmission electron microscopy (TEM)
Fixed exosome specimens at an optimal concentration were
placed onto 400-mesh carbon/formvar-coated grids and
allowed to absorb to the formvar for a minimum of 1min.
After rinsing in 1x PBS followed by distilled water, the grids
were allowed to dry and stained for contrast using uranyl
acetate. The samples were viewed with a Tecnai Bio Twin
transmission electron microscope (FEI), and images were
taken with an AMT CCD Camera (Advanced Microscopy
Techniques).
Immunoblotting
Immunoblot analysis was performed as described recently
with some minor modifications [11]. Briefly, serum exosomes
were harvested in RIPA buffer including Halt™ Protease- and
Phosphatase-Inhibitor-Cocktail (Thermo Scientific). 20µg of
protein were loaded and analyzed using acrylamide gels.
Subsequently, proteins were transferred onto PVDF mem-
branes (ImmobilonP) and blocked with 5% non-fat dry milk
or 5% BSA in PBS/0,05% Tween for 1hr. Subsequently, the
blot was incubated with primary antibodies against CD9
(dilution 1:500), TSG101 (dilution 1:200) and CD63 (dilution
1:200) at 4°C overnight. After incubation with horseradish
peroxidase coupled secondary antibodies, blots were devel-
oped with chemiluminescent reagent and visualized using an
Imagers G:Box Chemi XT4 (Syngene).
RNA isolation and real-time qPCR
Total RNA from exosomes was extracted by employing the Total
Exosome RNA & Protein Isolation Kit (Invitrogen) following the
manual´s instructions. RNA quality and concentration were eval-
uated using a NanoVueTM Plus spectral photometer (GE
Healthcare BioSciences). Total RNA was reversely transcribed
using the High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems). Fifty nanograms of the resulting cDNA
were further used for quantification by qPCR (SYBR Green PCR
Kit,Qiagen,Hilden,Germany) in a StepOnePlus System (Applied
Biosystems). Following primers were used: H19 Forward: 5′-
GCACCTTGGACATCTGGAGT-3′, Reverse: 5′-
TTCTTTCCAGCCCTAGCTCA-3′; HOTTIP Forward: 5′-
CCTAAAGCCACGCTTCTTTG-3′, Reverse: 5′-TGCAGGCT
GGAGATCCTACT-3′[14]; HULC: Forward: 5′-TCATGATG
GAATTGGAGCCTT-3′, Reverse: 5′-CTCTTCCTGGCTT
GCAGATTG-3′[15]; MALAT1 Forward: 5′-CGTCATTTAAA
GCCTAGTTAACGCA-3′, Reverse: 5′-GTTTCATCCTACCAC




The SPSS software package version 21.0 (Chicago, IL, USA)
Graph Pad and MedCalc were used for statistical analysis.
Mann-Whitney-U test was performed to compare the expres-
sion of lncRNAs in serum exosomes. Chi-squared (χ[2]) tests
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were applied to examine the correlation between the expres-
sion of exosomal lncRNAs and clinicopathological para-
meters. Receiver operating characteristic (ROC) curves were
used to determine the sensitivity and specificity, and to com-
pare the area under the curves (AUC) of exosomal lncRNAs.
Univariate survival analysis was performed using the Kaplan-
Meier method and differences in survival were calculated with
the log-rank test whilst the Cox proportional hazards regres-
sion model was conducted for multivariate testing. Results
were considered significant at a p-value less than 0.05.
Results
Patient characteristics
To conduct the study, we used cohort 1 consisting of 52
patients with CRC and 52 healthy donors from primary
CRC patients treated in Heidelberg, Germany. The second
cohort (cohort 2) was used to validate our findings and con-
sisted of 48 patients with CRC and 24 healthy donors. The
clinicopathological and patient characteristics have been sum-
marized in Table 1.
Identification of serum exosomes
Firstly, we sought out to determine the existence of exo-
somes in the serum from patients with CRC and healthy
donors. After extraction, extracellular vesicles (EV) were
measured using ZetaView® with a median size of
109.3 nm/EVs ranging from 73.2 – 136nm (Figure 1A).
TEM confirmed the presence of double-membrane vesicles
with a size range of 50–150nm (Figure 1B). Isolated EVs
were positive for common exosome markers [16] CD9,
CD81, CD63 and TSG 101 using immunoblot analyses
(Figure 1C), and calreticulin was used to control for poten-
tial cytoplasmic contamination, which was hardly expressed
in our samples. Fluorescent staining of TSG 101, CD9,
CD81 and C63 revealed that bead-bound EVs were strongly
positive for these exosomal markers (Figure 1D). Taken
together, we detected classical exosomes [16] with
a diameter of 50 – 150 nm enriched of exosome-related
proteins such as CD9, CD63, CD81 or TSG 101 in the
serum of healthy donors and patients with underlying dis-
eases [17,18].
Expression profile of exosomal long non-coding RNAs
H19, HOTTIP, HULC and MALAT in serum-derived
exosomes
Long non-coding RNAs (lncRNA) have been implicated to
contribute to the onset and progression of various diseases
[8], as these are known modulators of gene expression. We
focused specifically on four lncRNA (H19, HOTTIP,
MALAT1 and HULC) that have been associated with CRC
[19–25]. HOTTIP, MALAT1 and H19 are aberrantly
expressed in CRC and have been associated with a worse
prognosis and poor overall survival. These lncRNAs are
known regulators of the EMT transition, as they are involved
in the repression of tumor suppressive microRNAs, epige-
netic regulation of HOXA and EZH2 genes and the remodel-
ing of the chromatin complexes [26].
At first we wanted to investigate whether these lncRNA
can be detected in the serum-derived exosomes and found
that lncRNA H19, HOTTIP and HULC expression was
significantly decreased in serum-derived exosomes from
CRC patients compared to healthy donors (Figure 2A–C).
In contrast, no significant difference was observed of exo-
some-derived MALAT1 between healthy donors and
patients with CRC (Figure 2D). To validate our findings,
we used a second cohort of primary CRC and healthy
donors available to us. We found a similar trend of the
lncRNAs from cohort 1, suggesting that exosomal HOTTIP,
HULC and H19 are downregulated in primary CRC
patients. Next, we asked whether these lncRNAs are pre-
dictive of disease and performed ROC curve analysis for all
lncRNAs in both cohorts (Figure 3A, B). Exosomal
HOTTIP in healthy donors vs. cancer patients resulted in
an area under the curve (AUC) of 0.75 in cohorts 1 and 2
(Figure 3A, B, Supplementary Table 1). The AUC of exo-
somal HULC for healthy donors vs. cancer patients reached
0.77 (cohort 1) and 0.71 (cohort 2) (Figure 3A,
Supplementary Table 1). For H19, ROC curve analysis
showed an AUC value of 0.68 (cohort 1) and an AUC of
0.72 (cohort 2) in healthy donors vs. cancer patients (Figure
3A, Supplementary Table 1), whilst exosomal MALAT1
showed the lowest AUC of 0.61 and 0.62 in cohort 1 and
cohort 2.
Table 1. Univariate analysis (log-rank test) of prognostic parameters in primary
colorectal cancer of cohort 1 for overall survival. Data was missing for some
patients regarding parameters *Grading (n = 39 total), **Resection status
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Low expression of HOTTIP in exosomes and tissue of
primary CRC is a prognostic marker for decreased
overall survival
Next, we asked whether the levels of HOTTIP expression
might be indicative of patient outcome in our cohort 1 as
exosomal HOTTIP, HULC and H19 expression resulted in
a good differential between health and disease. For survival
analysis, we categorized the patients accordingly into low/
intermediate (<75th percentile) and high (≥75th percentile)
expression of exosomal lncRNA. Chi-square analysis revealed
no significant correlation between any histopathological para-
meter and the exosomal expression of HOTTIP, HULC or
H19 (data not shown). Univariate analysis by log-rank tests
showed a highly significant association between low/inter-
mediate expression of exosome-derived HOTTIP and poor
overall survival (Low/intermediate: 47.0 months, High:
80.4 months, p = 0.0009) (Figure 3C, Table 1), whilst no
statistical significance in overall survival was observed
depending on H19 and HULC expression (Supplementary
Figure 1A, 1B). In addition, the number of positive lymph
nodes (p = 0.026) was a significant prognostic marker (Table
1, Supplementary Figure 1C). Multivariate analysis confirmed
low expression of HOTTIP as an independent prognostic
marker for overall survival (HR: 4.5, CI: 1.69–11.98,
p = 0.0027), whereas the lymph node status failed to be
significant (Table 2). Next, we assessed the expression of
HOTTIP, H19 and MALAT1 in an independent cohort of
patients with CRC [27] to confirm our findings. Of note,
overall survival data was not available for HULC. In concor-
dance with the exosomal expression, low/intermediate expres-
sion of HOTTIP in primary CRC tissue was an indicator for
poor survival (Figure 3D) (HR: 0.6, CI: 0.37–0.98, p = 0.039)
in a cohort of 308 patients with CRC. We also found
a significantly lower expression of HOTTIP and H19 in
these tumor tissues (n = 2110) compared to normal tissue
(n = 40) (p < 0.05, respectively, Figure 3E, 3F) whilst no
significant difference in the expression of MALAT1 was
observed between normal and cancerous tissue (p = 0.25)
(Figure 3G). Taken together, we were able to show that
lncRNAs of exosomes can be used as a diagnostic marker.
Discussion
Molecular risk stratification in colorectal cancer is based on
histopathology markers such as stage, poor differentiation and
lymph node invasion, which currently fails to predict which
patient with local or advanced CRC will benefit from post-
surgical treatments with minimal adverse events or complica-
tions. This urgent clinical need could be met by using circulating
components of the blood as an attractive tool to discover highly
Figure 1. (a) Identification of serum exosomes by nanoparticle tracking analysis (NTA) using ZetaView®, (b) by transmission electron microscopy, (c) by Western Blot
for exosome-associated proteins and (d) by fluorescent NTA for exosome-associated protein markers.
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specific and non-invasive biomarkers. Recent studies have
shown the relevance of exosomal-associated protein signatures
and microRNAs in various diseases; hence the use of exosomal
lncRNAs as clinical biomarkers is still undergoing. Therefore, we
assessed a panel of four prominent lncRNAs that have been
described to play a pivotal role in CRC progression and disse-
mination [22,25,28–30]. In concordance with REMARK [31], we
evaluated the presence of these four selected candidate lncRNAs
in two independent cohorts. Both cohorts revealed that H19,
HULC and HOTTIP are decreased in exosomes derived from
serum of patients suffering from CRC. For exosomal H19, these
results have been observed in an independent dataset (www.
exorbase.org), as patients with CRC have lower H19 expression
in exosomes compared to healthy volunteers or patients with
coronary heart disease. Moreover, we show a concordant
decreased expression of H19 and HOTTIP in tumor tissue and
exosomes from cancer patients. In addition, we have not
observed any differential expression of MALAT1 in tissue and
exosomes from patients with CRC and control. These data
underline the hypothesis that tumor-derived exosomal cargo in
the blood circulation can reflect the expression profile of their
cells of origin. However, these results are contradicting the pro-
tumorigenic effects of H19 and HOTTIP in CRC that have been
reported so far [25,28]. The patient cohorts were mostly primary
CRC of the colon with no information about presence of metas-
tasis or resection status [25,28], whereby our cohorts included
mostly patients with non-metastatic CRC of the rectum that
underwent R0 resection. In addition, the biogenesis of exosomes
is a selective enrichment process by which the parental cell could
regulate the intracellular expression profile of distinct genes [32].
This implies that decreased secretion of exosomal lncRNAs may
result in an intracellular accumulation of these pro-tumorigenic
biomolecules. One limitation of our study is that the exosomal
lncRNAs could originate either from the tumor cells or from
other cells, e.g., platelets or leukocytes [32]. The current extrac-
tions are unselective, with no indication from which distinct cell
Figure 2. Expression analysis of exosomal long non-coding RNAs H19 (A), HOTTIP (B), HULC (C) and MALAT1 (D) in two independent cohorts (cohort 1, left panels,
cohort 2, right panels) in specimens from healthy control (HC) and patients with colorectal cancer (CRC). Expression level is indicated by the normalized Ct-values.
RNA BIOLOGY 1343
populations the exosomes derived and can therefore significantly
influence the results. In order to address this hypothesis, it would
be necessary to selectively enrich tumor exosomes from the
blood using specific surface markers prior to the expression
analysis of lncRNAs such as HOTTIP. Another limiting factor
of this study is the patient annotation for cohort 1 and outcome
data for cohort 2. We were not able to correlate our findings to
the genetic composition of the CRC patients from cohort 1 as the
KRAS/BRAF and microsatellite stability status was not estab-
lished. Cohort 2, which is a prospective study, had no overall
survival data available at the time of submission.
Moreover, due to the small sample size of serum exosomes,
we have to consider the possibility that the retrospective
cohort does not approximate the true model for the entire
population, suggesting a relative risk of overfitting, which may
have caused a bias of the results of our multivariate analysis.
This might explain the non-significant association of overall
survival with traditional risk factors including pT-stage. To
address such bias, additional prospective translational multi-
center studies are needed to confirm HOTTIP as a non-
invasive prognostic marker in colorectal cancer in the near
future.
Overall, our study provides new insights into diagnostic of
exosomes and its enclosed lncRNA cargo for patients with
CRC. We show that the lncRNA HOTTIP has not only the
Figure 3. ROC curve analysis of exosomal long non-coding RNAs H19 (green), HOTTIP (blue), HULC (grey) and MALAT1 (violet) from patients with colorectal cancer
and healthy control (a) of cohort 1 and (b) cohort 2. (c) Kaplan-Meier analysis of overall survival in patients with colorectal cancer expressing high (red line) or low
(black line) serum-derived exosomal HOTTIP. (d) Kaplan-Meier analysis of overall survival in patients with colorectal cancer and high (red line) or low (black line)
expression of HOTTIP in primary colorectal cancer. Data was generated using KM-plotter. (e-g) Expression analysis of (e) HOTTIP, (f) H19 and (g) MALAT1 in colorectal
cancer tissue or normal tissue. Data was generated using KM-plotter.
Table 2. Multivariate analysis (Cox proportional hazards regression model) of









Age (< median vs. ≥ median) 1.581 0.591–4.229 0.3618
Gender (female vs. male) 0.638 0.215–1.890 0.4169
pT-Stage (pT 1/2 vs. pT 3/4) 2.496 0.565–11.030 0.2275
Lymph node metastasis (positive
vs negative)
1.776 0.642–4.912 0.2686
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potential to identify patients with CRC but could serve as
a valuable surrogate biomarker for pre-surgical risk stratifica-
tion as HOTTIP expression significantly predicted the survi-
val time after surgery. This warrants further studies to (a)
determine the diagnostic implications by combining estab-
lished CRC markers and the expression of exosomal
HOTTIP in patients suspected to suffer from CRC and (b)
investigate the change of expression of lncRNA during disease
progression and in response to therapy.
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